Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer

NCT02124421 is registered in ClinicalTrials.gov with Mercy Medical Center as lead sponsor.

NCT NCT02124421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02124421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer
Lead sponsor
Mercy Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 30, 2014
Completion date
April 30, 2028
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian cancer, fallopian tube cancer, fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma, stage iii ovarian cancer, stage iv ovarian cancer